哌柏西利治疗HR+/HER2-乳腺癌新进展

Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer

摘要: 哌柏西利作为第一个上市的细胞周期蛋白依赖性激酶4和6抑制剂，显著改善了激素受体阳性、人表皮生长因子受体-2阴性乳腺癌的生存。哌柏西利的开发是抗肿瘤药物发展的一个重要里程碑。本文回顾了哌柏西利作用机制，总结了药物相关临床试验、相关不良反应以及药物应用等问题。

Abstract: As the first cyclin-dependent kinases 4 and 6 inhibitors, palbociclib significantly improved the survival of the patients with the hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer. Palbociclib is a crucial landmark in the development history of antineoplastic drugs. This article reviews the mechanism of palbociclib, and summarizes the clinical trials, side effects, and the application of palbociclib.